Evidence map›Paper›PMID 26657484›Full record

ArticlePloS one2015

Multi-Angle Effector Function Analysis of Human Monoclonal IgG Glycovariants.

Tetyana Dashivets, Marco Thomann, Petra Rueger, Alexander Knaupp, Johannes Buchner, Tilman Schlothauer

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed
8.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 101 citations in OpenAlex.

  1. Article
  2. Article
  3. IgG N-glycosylation in autoimmune diseases.Frontiers in immunology · 2026
    Review
  4. Antibody glycosylation in neuroimmune diseases.Journal of translational medicine · 2025
    Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Immunomodulation of Antibody Glycosylation through the Placental Transfer.International journal of molecular sciences · 2023
    Review
  17. Review
  18. Article
  19. Study on antibody Fc-glycosylation for optimal effector functions.Chemical communications (Cambridge, England) · 2023
    Article
  20. Universal chimeric FcActa pharmaceutica Sinica. B · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Tetyana DashivetsBiochemical and Analytical Research, Large Molecule Research, Roche Pharma Research and Early Development (pRED), Roche Innovation Center, Penzberg, Germany.
Marco ThomannPharma Biotech Development Penzberg, Roche Diagnostics GmbH, Penzberg, Germany.
Petra RuegerBiochemical and Analytical Research, Large Molecule Research, Roche Pharma Research and Early Development (pRED), Roche Innovation Center, Penzberg, Germany.
Alexander KnauppBiochemical and Analytical Research, Large Molecule Research, Roche Pharma Research and Early Development (pRED), Roche Innovation Center, Penzberg, Germany.
Johannes BuchnerCenter for Integrated Protein Science Munich, Department Chemie, Technische Universität München, 85748, Garching, Germany.
Tilman SchlothauerBiochemical and Analytical Research, Large Molecule Research, Roche Pharma Research and Early Development (pRED), Roche Innovation Center, Penzberg, Germany.
Technical University of Munich · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Therapeutic performance of recombinant antibodies relies on two independent mechanisms: antigen recognition and Fc-mediated antibody effector functions. Interaction of Fc-fragment with different FcR triggers antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity and determines longevity of the antibody in serum. In context of therapeutic antibodies FcγRs play the most important role. It has been demonstrated that the Fc-attached sugar moiety is essential for IgG effector functionality, dictates its affinity to individual FcγRs and determines binding to different receptor classes: activating or inhibitory. In this study, we systematically analyze effector functions of monoclonal IgG1 and its eight enzymatically engineered glycosylation variants. The analysis of interaction of glycovariants with FcRs was performed for single, as well as for antigen-bound antibodies and IgGs in a form of immune complex. In addition to functional properties we addressed impact of glycosylation on the structural properties of the tested glycovariants. We demonstrate a clear impact of glycosylation pattern on antibody stability and interaction with different FcγRs. Consistent with previous reports, deglycosylated antibodies failed to bind all Fcγ-receptors, with the exception of high affinity FcγRI. The FcγRII and FcγRIIIa binding activity of IgG1 was observed to depend on the galactosylation level, and hypergalactosylated antibodies demonstrated increased receptor interaction. Sialylation did not decrease the FcγR binding of the tested IgGs; in contrast, sialylation of antibodies improved binding to FcγRIIa and IIb. We demonstrate that glycosylation influences to some extent IgG1 interaction with FcRn. However, independent of glycosylation pattern the interaction of IgG1 with a soluble monomeric target surprisingly resulted in an impaired receptor binding. Here, we demonstrate, that immune complexes (IC), induced by multimeric ligand, compensated for the decreased affinity of target bound antibody towards FcRs, showing the importance of the IC-formation for the FcR- mediated effector functions.

Indexed as

Antibodies, MonoclonalAntibody AffinityAntigen-Antibody ComplexCarbohydrate SequenceCell LineChromatography, AffinityGalactoseGene ExpressionGlycosylationHumansImmunoglobulin Fc FragmentsImmunoglobulin GMolecular Sequence DataProtein BindingProtein EngineeringProtein StabilityAntibodies, MonoclonalAntigen-Antibody ComplexFc gamma receptor IIAFCGR1A protein, humanGalactoseImmunoglobulin Fc FragmentsImmunoglobulin GReceptors, IgGRecombinant ProteinsSialic Acids

Identifiers

PMID26657484
PMCPMC4676693
OpenAlexW2190603070

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.